A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel

Yi-Long Wu¹, Chang-Li Wang², Mei-Lin Liao³, Zhong-Zhen Guan⁴, Chen-Yan Gao⁵, Shun Lu³, Ming-Fang Zhao⁶, Jie Wang⁷, Xiao-Qing Liu⁸, Jin-Ji Yang¹, Jun Liang⁹, Wei-Min Mao¹⁰, Bao-Hui Han³, Xu-Chao Zhang¹, Yong Song¹¹, Ji-Feng Feng¹², Sheng-Lin Ma¹³, Gang Wu¹⁴, Cai-Cun Zhou¹⁵, Ke-Neng Chen¹⁶, Ying Cheng¹⁷, Yong He¹⁸, Chun Chen¹⁹, Qun Wang²⁰, Ji-Zhen Lin²¹, Bo Zhu²², Yun-Peng Liu⁶, Yi Hu²³, Gui-Bin Qiao²⁴, Qing Zhou¹, Qi-Bin Song²⁵, Nan Wu¹⁶, Lin Wu²⁶, Cheng Huang²⁷, Xiao-Long Fu³, Jian-Ping Xiong²⁸, Jie Hu²⁰, Cheng-Ping Hu²⁹, Jian-Hua Chang³⁰, Qiong Zhao³¹, Jun Zhao¹⁶, Peng-Hui Zhou⁴, Zhi-Yong Ma³², Yuan Chen³³, He-Long Zhang³⁴, Fan Yang³⁵, Jian-Jun Wang¹⁴, Yue-Yin Pan³⁶, Xue-Ning Yang¹, Yun Fan¹⁰, Zhe Liu³⁷, Wen Fan³⁰, Nong Yang²⁶, Yan-Fang Guan³⁸, Hao Sun¹, Wen-Zhao Zhong¹

Affiliations

¹ Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
² Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
³ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200240, China.
⁴ Sun Yat-sen University Cancer Center, Guangzhou 510030, China.
⁵ Center for Food and Drug Inspection of China Food and Drug Administration, The First Hospital of China Medical University, Shenyang 110001, China.
⁶ Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China.
⁷ Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
⁸ Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Beijing 100071, China.
⁹ Department of Oncology, Peking University International Hospital, Beijing 102206, China.
¹⁰ Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310000, China.
¹¹ Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210008, China.
¹² Department of Chemotherapy, Jiangsu Cancer Hospital, Hangzhou 310000, China.
¹³ Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou 310003, China.
¹⁴ Department of Oncology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
¹⁵ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200092, China.
¹⁶ Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing 100142, China.
¹⁷ Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.
¹⁸ Department of Respiratory Medicine, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing 400042, China.
¹⁹ Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fujian 350001, China.
²⁰ Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
²¹ Institute of Immunotherapy, Fujian Medical University, Fuzhou 350004, China.
²² Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing 400030, China.
²³ Department of Internal Oncology, 301 General Hospital, Beijing 100853, China.
²⁴ Department of Thoracic Surgery, The General Hospital of Guangzhou Military Command, Guangzhou 510010, China.
²⁵ Cancer Center of Renmin Hospital, Wuhan University, Wuhan 430070, China.
²⁶ Department of Oncology, Hu Nan Provincial Tumor Hospital, Changsha 410006, China.
²⁷ Department of Oncology, Fujian Provincial Cancer Hospital, Fuzhou 350011, China.
²⁸ Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330039, China.
²⁹ Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
³⁰ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
³¹ Department of Thoracic Oncology, The First Affiliated Hospital, ZheJiang University, Hangzhou 310006, China.
³² Department of Medical Oncology, Henan Cancer hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, China.
³³ Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
³⁴ Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710006, China.
³⁵ Department of Thoracic Surgery, Peking University People Hospital, Beijing 100044, China.
³⁶ Department of Oncology, Anhui Medical University, Hefei 230032, China.
³⁷ Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
³⁸ Beijing Gene+ Technology, Beijing 102208, China.

PMID: 30050780
PMCID: PMC6037958
DOI: 10.21037/tlcr.2018.04.15

Review

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel

Yi-Long Wu et al. Transl Lung Cancer Res. 2018 Jun.

. 2018 Jun;7(3):428-436.

doi: 10.21037/tlcr.2018.04.15.

Authors

Affiliations

¹ Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
² Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
³ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200240, China.
⁴ Sun Yat-sen University Cancer Center, Guangzhou 510030, China.
⁵ Center for Food and Drug Inspection of China Food and Drug Administration, The First Hospital of China Medical University, Shenyang 110001, China.
⁶ Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China.
⁷ Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
⁸ Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Beijing 100071, China.
⁹ Department of Oncology, Peking University International Hospital, Beijing 102206, China.
¹⁰ Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310000, China.
¹¹ Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210008, China.
¹² Department of Chemotherapy, Jiangsu Cancer Hospital, Hangzhou 310000, China.
¹³ Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou 310003, China.
¹⁴ Department of Oncology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
¹⁵ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200092, China.
¹⁶ Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing 100142, China.
¹⁷ Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.
¹⁸ Department of Respiratory Medicine, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing 400042, China.
¹⁹ Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fujian 350001, China.
²⁰ Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
²¹ Institute of Immunotherapy, Fujian Medical University, Fuzhou 350004, China.
²² Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing 400030, China.
²³ Department of Internal Oncology, 301 General Hospital, Beijing 100853, China.
²⁴ Department of Thoracic Surgery, The General Hospital of Guangzhou Military Command, Guangzhou 510010, China.
²⁵ Cancer Center of Renmin Hospital, Wuhan University, Wuhan 430070, China.
²⁶ Department of Oncology, Hu Nan Provincial Tumor Hospital, Changsha 410006, China.
²⁷ Department of Oncology, Fujian Provincial Cancer Hospital, Fuzhou 350011, China.
²⁸ Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330039, China.
²⁹ Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
³⁰ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
³¹ Department of Thoracic Oncology, The First Affiliated Hospital, ZheJiang University, Hangzhou 310006, China.
³² Department of Medical Oncology, Henan Cancer hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, China.
³³ Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
³⁴ Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710006, China.
³⁵ Department of Thoracic Surgery, Peking University People Hospital, Beijing 100044, China.
³⁶ Department of Oncology, Anhui Medical University, Hefei 230032, China.
³⁷ Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
³⁸ Beijing Gene+ Technology, Beijing 102208, China.

PMID: 30050780
PMCID: PMC6037958
DOI: 10.21037/tlcr.2018.04.15

Abstract

The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.

Keywords: Lung cancer; consensus; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15. 10.1038/nm1100 - DOI - PMC - PubMed
1. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68. 10.1016/S1470-2045(13)70510-2 - DOI - PubMed
1. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10:371-4. 10.3816/CLC.2009.n.052 - DOI - PubMed
1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
1. Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 2012;12:923-37. 10.1517/14712598.2012.685715 - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel

Affiliations

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources